Oncotarget

Oncotarget Videos

Dynavax Technologies's Dr. Mary J. Janatpour talks about her Publication in the Open-access Bio-medical Journal Oncotarget

Correspondence to - Mary J. Janatpour, email: mjanatpour@dynavax.com

Keywords: TLR9, SD-101, cyclophosphamide, immune therapy, innate immunity



Copyright © 2020 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC